X4 Pharmaceuticals (XFOR) Cash from Investing Activities (2017 - 2025)

X4 Pharmaceuticals' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at $16.8 million for Q4 2025.

• Quarterly Cash from Investing Activities rose 295.44% year-over-year to $16.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.2 million (down 87.83% YoY) and the FY2025 annual result came in at $8.2 million, down 87.83% from the prior year.
• Cash from Investing Activities was $16.8 million for Q4 2025 at X4 Pharmaceuticals, up from -$28.7 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $96.9 million in Q2 2024 and bottomed at -$28.7 million in Q3 2025.
• A 5-year average of $3.0 million and a median of -$62000.0 in 2021 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 2083.25% in 2024, while the deepest fall reached 59033.33% in 2024.
• X4 Pharmaceuticals' Cash from Investing Activities stood at -$13000.0 in 2021, then plunged by 161.54% to -$34000.0 in 2022, then slumped by 14114.71% to -$4.8 million in 2023, then sank by 78.38% to -$8.6 million in 2024, then surged by 295.44% to $16.8 million in 2025.
• Business Quant data shows XFOR's Cash from Investing Activities at $16.8 million in Q4 2025, -$28.7 million in Q3 2025, and $23.1 million in Q2 2025.